As Novo Nordisk transitions from the leadership of longtime CEO Lars Fruergaard Jørgensen to newly appointed chief Maziar ...

By May of 2025, Novo's now-former chief executive, Lars Fruergaard Jørgensen, announced that he would be stepping down, ...

Maziar Mike Doustdar takes office as NVO's new CEO, bringing a proven global growth record to tackle rising obesity market ...

As chief executive of Novo Nordisk from 2017 until earlier this month, I had a front-row seat to the promise and limitations of pharmaceutical interventions. These interventions have shown potential ...

Novo Nordisk’s stock popped Monday after it announced a cash discount for uninsured Ozempic users and gained FDA approval for ...

Several months after unveiling its direct-to-consumer NovoCare Pharmacy service with the launch of a $499 cash-pay option for ...

The pharma giant has almost doubled the size of its workforce over the last five years but is now looking to tighten cost ...

Novo Nordisk is slashing the cost of Ozempic for cash-paying patients after the diabetes shot became the poster child for ...

U.S.-listed shares of Novo Nordisk sank in premarket trading Tuesday after the Danish drugmaker cut its full-year outlook and ...

Novo Nordisk expects continued competition from copycat versions of its blockbuster Wegovy obesity drug this year and could ...

Novo Nordisk has plummeted back to Earth after a stunning rise driven by Ozempic and Wegovy. Can the storied Danish pharma ...

The health and beauty firm behind the Myprotein brand has said its profits will fall by £13m because of the high price of key ingredient whey. Once regarded as a by-product in cheese-making, whey ...